Clinical Trials Logo

Melanosis clinical trials

View clinical trials related to Melanosis.

Filter by:

NCT ID: NCT05626881 Recruiting - Melasma Clinical Trials

Efficacy of Intralesional PRP +/- Topical Silymarin in the Treatment of Melasma

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Melasma is an acquired disorder of melanogenesis leading to hyperpigmentation and manifested by symmetrical brown to gray-black macules and patches with serrated irregular edges . It occurs especially in sun-exposed areas and affects young to middle-aged women. It is most commonly seen on the face and less commonly on the neck, arms, and chest . Platelet rich plasma (PRP) is defined as a small volume of autologous plasma that contains a high concentration of platelets obtained by centrifugation of autologous blood and subsequent suspension of platelets

NCT ID: NCT05326997 Recruiting - Melasma Clinical Trials

Treatment of Melasma With Yellow Light Compared to Tranexamic Acid

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Photobiomodulation (PBM) has been suggested as an alternative treatment for Melasma, showed by the in vitro data, inhibition of the tyrosinase enzyme and reduction in the pigment content by autophagy. This treatment compares with tranexamic acid, where it acts on similar pathways of melanogenesis. A total of 54 female participants, phototype scale Fitzpatrick ll - lV will be recruited which will be distributed among two groups: Light + placebo Home Care cosmetic product and Light sham + Home Care cosmetic product with tranexamic acid. The treatments will consist of 90 days, with application of photobiomodulation (PBM) once a week and application of the cosmetic product twice a day.

NCT ID: NCT04765930 Recruiting - Melasma Clinical Trials

Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Melasma is a common, acquired, esthetically disfiguring hypermelanosis of the face. Melasma is considered a disappointing challenge when treatment options are addressed. Diverse treatment modalities such as retinoic acid, hypo-pigmenting agents like hydroquinone, azelaic acid, and kojic acid, chemical peels, microdermabrasion, and lasers have been tried for the treatment of melasma. There is no universally proven therapy that induces and maintains remission of the condition. Q-switched: Nd YAG laser toning and platelet rich plasma (PRP) are promising treatments for melasma.The aim of this work is evaluate the efficacy and safety of combined PRP and Q-switched: NdYAG laser in the treatment of melasma using clinical assessment, in addition to assessment of Melanin Index and Erythema Index.

NCT ID: NCT04597203 Recruiting - Melasma Clinical Trials

Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial

Start date: October 2020
Phase: N/A
Study type: Interventional

This study aims to assess the efficacy and safety of using combination of 755-nm picosecond alexandrite laser and 2% hydroquinone compared with 2% hydroquinone alone for the treatment of melasma: A randomized split-face controlled trial

NCT ID: NCT04548817 Recruiting - Clinical trials for Large Cutaneous Melanocytic Nevi

Neurocutaneous Melanocytosis Registry

Start date: September 3, 2020
Phase:
Study type: Observational [Patient Registry]

This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).

NCT ID: NCT04353050 Recruiting - Melanoma Clinical Trials

Atypical MOLes and Melanoma Early Detection Study (MoleMed)

MoleMed
Start date: April 1, 2020
Phase: N/A
Study type: Interventional

This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms. In retrospective cohorts genetics markers will be identified. In prospective cohort non-invasive adhesive system will be tested to identify malignant or benign lesions with prespecified sensitivity and specificity compared to other non-invasive techniques (i.e. dermoscopy) and using histopathological examination as a "golden standard".

NCT ID: NCT04308421 Recruiting - Vitiligo Clinical Trials

Efficacy of Red Light in the Treatment of Pigmentary Disorders

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Pigmentary disorders such as melasma, lichen planus pigmentosus and vitiligo can significantly affect patients' quality of life. Treatment responses are usually slow and typically have limited efficacy. In recent years, low level laser therapy has been an emerging treatment modality for androgenetic alopecia, acne, wound healing and photorejuvenation. This is a prospective, double-blind, split-body, randomized controlled trial assessing the efficacy of low level laser therapy with red light for pigmentary disorders such as, melasma, lichen planus pigmentosus and vitiligo.

NCT ID: NCT03686787 Recruiting - Melasma Clinical Trials

Oral Tranexamic Acid and Laser for Treatment of Melasma

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

NCT ID: NCT03475524 Recruiting - Melasma Clinical Trials

USE THE SYSTEMIC METFORMIN IN MELASMA

Start date: April 1, 2019
Phase: Phase 4
Study type: Interventional

Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV radiation, pregnancy, and exogenous hormones (such as oral contraceptives,thyroid hormones, and hormone replacement therapy). Other factors implicated are phototoxic drugs, anticonvulsant medications,and the use of certain cosmetics. Types of melasma are epidermal, dermal and mixed according to location of melanin.

NCT ID: NCT03308370 Recruiting - Melasma Clinical Trials

Platelet Rich Plasma in Treatment of Melasma

Start date: November 1, 2017
Phase: Phase 3
Study type: Interventional

Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challenging and discouraging. Platelet rich plasma has been used over the last several years as an effective treatment in various surgical and medical fields. In recent years, Platelet rich plasma has also started to be used in the field of cosmetology. This study is designed to evaluate the therapeutic effect of platelet rich plasma in melasma.